alexa Twenty Years in the Making: Overall Survival Increased with the Addition of Hormonal Therapy to Salvage Radiation Following Radical Prostatectomy | Open Access Journals
ISSN: 2168-9857
Medical & Surgical Urology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Twenty Years in the Making: Overall Survival Increased with the Addition of Hormonal Therapy to Salvage Radiation Following Radical Prostatectomy

Marc R Matrana*

Clinical Cancer Research, Ochsner Cancer Institute, USA

Corresponding Author:
Marc R Matrana
Associate Director of Clinical Cancer Research
Ochsner Cancer Institute, USA
Tel: 504-842-3910
E-mail: mamatrana@ochsner.org

Received Date: July 18, 2016; Accepted Date: July 19, 2016; Published Date: July 27, 2016

Citation: Matrana MR (2016) Twenty Years in the Making: Overall Survival Increased with the Addition of Hormonal Therapy to Salvage Radiation Following Radical Prostatectomy. Med Sur Urol 5:e117. doi:10.4172/2168-9857.1000e117

Copyright: © 2016 Matrana MR. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Medical & Surgical Urology

Editorial

Prostate cancer is the leading malignancy in men and accounts for well over 25,000 deaths in the United States each year. About 40% of men diagnosed with localized prostate cancer will undergo prostatectomy, and a number of these will draw biochemical relapse long before metastatic disease can be found on scans. The proper management of these complex patients has challenged clinicians for decades. Dr. William U. Shipley of Massachusetts General Hospital and Harvard Medical School has contemplated one aspect of this problem for many years, designing a trial 20 years ago whose results were reported earlier this year at the 2016 Genitourinary Cancer Symposium.

Dr. Shipley’s trial, RTOG 9601, randomized 760 American and Canadian men who had T3pN0 prostate cancer or T2pN0 with positive surgical margins, and elevated PSA following radical prostatectomy to two arms. In the study arm, patients received both radiation and 24 months of hormonal therapy with bicalutamide; and the comparator arm patients received radiation and placebo. Patient were treated on the trial from 1998 to 2003, and then followed for a median of 13.0 years. Patients had an elevated PSA level no higher than 4.0 ng/mL at study entry, with the median PSA being 0.6 ng/mL at baseline.

The results strongly favored adding hormonal therapy to radiation in this setting, with the strongest benefits being shown in patients with the highest risk disease (those with higher Gleason scores, positive surgical margins, and higher PSA levels at baseline). The primary study endpoint of overall survival revealed that at 10 years, 82% of patients who receive bicalutamide in addition to radiation were alive, as compared with 78% assigned to radiation with placebo. This corresponds to a 23% risk reduction in death (HR 0.77, 95% CI [0.59, 0.99]; p = 0.040).

The addition of hormonal therapy to salvage radiation in biochemical recurrence also significantly decreased the risk of metastasis, as well as the rate of disease related death. At the 10-year time point, the cumulative incidence of metastatic prostate cancer reached only 11% in those who received hormonal therapy, as compared with 19% in those who received placebo (HR 0.63, 95% CI [0.46, 0.87]; p=0.005). And, at 10 years, only 4.5% of patients treated with hormonal therapy had died of prostate cancer, while 10.1% of patients in the comparator arm had succumb to the disease (HR 0.49, 95% CI [0.32, 0.74]; p<0.001).

The number needed to treat to save one man dying from prostate cancer is only 12, a small investment given the low toxicity and affordability of hormonal therapy. These results, twenty years in the making, herald those of similar trials conducted in Britain and France, who results are still forthcoming. While awaiting those data, it seems prudent to consider the addition of extended bicalutamide to radiation in men with PSA-only recurrence following prostectomy, especially those with high risk features.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 7802
  • [From(publication date):
    August-2016 - May 23, 2017]
  • Breakdown by view type
  • HTML page views : 7758
  • PDF downloads :44
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version